Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab [Immunology and Inflammation]

Rational modulation of the immune response with biologics represents one of the most promising and active areas for the realization of new therapeutic strategies. In particular, the use of function blocking monoclonal antibodies targeting checkpoint inhibitors such as CTLA-4 and PD-1 have proven to be highly effective for the systemic...

http://ift.tt/2qSWSej